CONMED (NYSE:CNMD) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS

CONMED (NYSE:CNMD) posted its quarterly earnings data on Wednesday. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.14, Zacks reports. CONMED had a return on equity of 13.84% and a net margin of 10.23%. CONMED updated its FY 2025 guidance to 4.250-4.400 EPS.

CONMED Price Performance

Shares of CNMD traded down $0.03 during mid-day trading on Friday, hitting $67.33. 333,643 shares of the company were exchanged, compared to its average volume of 443,924. The company has a 50 day moving average of $70.53 and a 200-day moving average of $70.20. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.06 and a current ratio of 2.27. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of 15.90, a price-to-earnings-growth ratio of 1.04 and a beta of 1.46. CONMED has a 1-year low of $61.05 and a 1-year high of $88.60.

CONMED Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 3rd. Stockholders of record on Friday, December 20th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date was Friday, December 20th. CONMED’s dividend payout ratio (DPR) is presently 18.87%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Needham & Company LLC reduced their target price on CONMED from $97.00 to $91.00 and set a “buy” rating on the stock in a report on Thursday. Wells Fargo & Company lowered their price objective on shares of CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a research report on Thursday. JPMorgan Chase & Co. lowered shares of CONMED from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $85.00 to $70.00 in a research report on Thursday. Stifel Nicolaus upped their price objective on shares of CONMED from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, StockNews.com cut CONMED from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $77.20.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.